Caution: Slow Down Ahead

April 2010
Pharmaceutical Representative;Apr2010, Vol. 40 Issue 4, p9
The article reports on the "Pharmaceutical Company Outlook to 2014," by Datamonitor which says that prescription drug sales will rise only at 1.2% until 2014, which it attributed to generics competition and patent expirations.


Related Articles

  • Despite travails, it was still an up year for most community R.Ph.s. Ukens, Carol // Drug Topics;12/10/2001, Vol. 145 Issue 23, p31 

    Describes the financial performance of the pharmaceutical industry in 2001. Expectations of independents and chain drug stores; Statistics on net profits; Significance to local retail trade.

  • 30 years of growth in Canadian pharmaceutical sales projected to end in 2011.  // Canadian Pharmacists Journal (Allen Press Publishing Services In;May/Jun2011, Vol. 144 Issue 3, p109 

    The article presents the report conducted by IMS Brogan which shows that the pharmaceutical sales in Canada is forecasted to decline by 6 percent in 2011.

  • New Rules for a New Africa. Saba, Joseph // Pharmaceutical Executive;Aug2013, Vol. 33 Issue 8, p30 

    The article discusses Africa as a favorite destination for pharmaceutical companies as they are in search of opportunities in the emerging economies due to limited growth prospects in mature markets of Europe and the U.S. It is informed that sales of pharmaceuticals are expected to increase...

  • Pharma 2005. Arlington, Steve // Pharmaceutical Executive;Jan2000, Vol. 20 Issue 1, p74 

    Analyzes the problems the pharmaceutical industry will face by year 2005. Reasons behind the increasing research and development spending of the pharmaceutical and biotechnology industries; Forecast on the sales growth of the industry; Potential benefit of the Human Genome Project to the...

  • Novartis Reaffirms Positive Outlook.  // Chemical Market Reporter;7/2/2001, Vol. 260 Issue 1, p10 

    Reports of the decision of Novartis Pharmaceuticals Corp. to reaffirm its sales outlook in 2001. Profit warning issued by Merck and Co.; Expansion of the Novartis franchise for the cancer drug Gleevac; Move to divestment its U.S. rights to several central nervous system drugs.

  • Licensing Deals on Rise.  // Chain Drug Review;3/15/2010, Vol. 32 Issue 6, p82 

    The article reports on the forecast by BioPharm Insight, which states that the pharmaceutical sales is expected to slowdown despite the increase in biotechnology and pharmaceutical licensing in the U.S.

  • PHARMACEUTICAL PREPARATION MFG. INDUSTRY (NAICS 325412).  // United States Pharmaceutical Preparation Manufacturing Industry ;2016, p1 

    An industry report of the pharmaceutical preparation manufacturing industry in the U.S. during 2015-2017 is presented from publisher Barnes Reports, with topics including estimated sales, estimated number of employees, and estimated number of establishments.

  • Drug stores anticipate robust holiday sales. Alexander, Antoinette // Drug Store News;12/15/2003, Vol. 25 Issue 17, p1 

    Drug stores have been as busy as Santa's elves, shoring up the front end with toys, last-minute stocking stuffers and even Christmas trees to prepare for what some industry observers say could be a jolly holiday shopping season. If holiday sales predictions ring true, retail sales could increase...

  • SEE pharmaceutical market healthy in 2010. Stamov, Valentin; Pavlova, Iskra // SEE Top 100;2011, p46 

    The article focuses on the condition of the pharmaceutical market in 2010 in Southeast Europe (SEE). It notes that sales of pharmaceuticals in the SEE region are influenced by generic drugs. It claims that there is a growth in the pharmaceutical market in Bulgaria in terms of value. It also...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics